Hisun Pharma: HSK39004 inhalation powder aerosol included in breakthrough therapy drug program

Hikov announcement, the company learned on April 7, 2026 that HSK39004 inhalation powder aerosol has been officially included in the "List of Breakthrough Therapeutic Varieties" by the National Medical Products Administration Drug Evaluation Center. This will greatly promote the research and development process of new drugs in this field, bringing new hope for the treatment of patients with chronic obstructive pulmonary disease. HSK39004 is a new targeted small molecule inhibitor independently developed by the company with its own intellectual property rights, clinically intended for the treatment of chronic obstructive pulmonary disease.